Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Rosiglitazone: a thunderstorm from scarce and fragile data.

Mulrow CD, Cornell J, Localio AR.

Ann Intern Med. 2007 Oct 16;147(8):585-7. No abstract available.

PMID:
17938398
2.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Singh S, Loke YK, Furberg CD.

JAMA. 2007 Sep 12;298(10):1189-95.

PMID:
17848653
3.
4.

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

Diamond GA, Bax L, Kaul S.

Ann Intern Med. 2007 Oct 16;147(8):578-81. Epub 2007 Aug 6.

PMID:
17679700
5.

Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL.

Ann Intern Med. 2007 Sep 18;147(6):386-99. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.

PMID:
17638715
6.

Rosiglitazone for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006063. Review.

PMID:
17636824
7.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group..

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

8.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

9.

The DREAM trial.

Nissen SE.

Lancet. 2006 Dec 9;368(9552):2049; author reply 2050-1. No abstract available.

PMID:
17161720
10.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group..

N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.

11.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators., Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.

Lancet. 2006 Sep 23;368(9541):1096-105. Erratum in: Lancet. 2006 Nov 18;368(9549):1770.

12.

A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.

Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T.

Diabetes Care. 2006 Jan;29(1):101-6.

PMID:
16373904
13.

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group..

N Engl J Med. 2005 Dec 22;353(25):2643-53.

14.

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.

Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ.

Curr Med Res Opin. 2005 Dec;21(12):2029-35.

PMID:
16368054
15.

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group..

Diabetes Obes Metab. 2006 Jan;8(1):49-57.

PMID:
16367882
16.
17.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators..

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598
18.

Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study.

Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW.

Arch Intern Med. 2005 Sep 12;165(16):1910-6.

PMID:
16157837
19.

Alpha-glucosidase inhibitors for type 2 diabetes mellitus.

Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003639. Review.

PMID:
15846673
20.

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study.

Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV.

Diabetes Care. 2005 Mar;28(3):539-43.

PMID:
15735184

Supplemental Content

Support Center